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Purpose: Limited data are available to describe the
effectiveness of darbepoetin alfa (DA) in terms of
hemoglobin (Hb) and transfusion outcomes when
initiated at Hb r10 g/dL (the threshold speciﬁed in
the summary of prescribing characteristics). We as-
sessed DA, initiated according to current labeling (Hb
r10 g/dL), in chemotherapy-induced anemia (CIA).
Methods: Data for patients with cancer and CIA
who initiated DA at Hb r10 g/dL were extracted
from a database of Amgen-sponsored trials. A com-
parative analysis was limited to randomized, con-
trolled trials in patients treated with DA or control
(placebo/best supportive care). Data for the DA arm(s)
of randomized, multiple-arm, or prospective, single-
arm trials were also extracted (DA-only analysis; non–
front-loaded studies only). Outcomes included Hb
increase Z1 g/dL or Z2 g/dL during the ﬁrst 12
weeks of treatment. Crude and Kaplan–Meier pro-
portions of patients who experienced each outcome
and time (days) to each outcome were summarized by
treatment arm. Meta-analysis (ﬁxed-effects inverse-
variance method) was performed to compare out-
comes for DA with control.
Findings: The comparative analysis included 4
studies (2 in lung cancer, 1 in lymphoproliferative
disease, and 1 in non-myeloid malignancy: DA, n ¼
261; control, n ¼ 273). The DA-only analysis included
15 studies (n ¼ 3768). In comparative analyses, more
patients who received DA than placebo achieved Hb
increase ofZ1 g/dL (ﬁxed-effects hazard ratio [HR] ¼
2.07; 95% CI, 1.62–2.63) or Z2 g/dL (HR ¼ 2.91;
95% CI, 2.09–4.06). Median times toZ1 g/dL orZ2
g/dL increase were 43 or 78 days for DA (not122evaluable for placebo). Transfusions were less com-
mon in patients who received DA (HR ¼ 0.58; 95%
CI, 0.44–0.77). Addition of 2 dose-ﬁnding studies did
not change the ﬁndings of the main comparative
analysis. Results were similar in the DA-only analyses.
Implications: This is the ﬁrst patient-level meta-
analysis, to our knowledge, to evaluate the efﬁcacy in
terms of Hb response of DA treatment when initiated
according to current product labeling in patients with
CIA. Limitations include the small number of studies
and patients eligible for inclusion in the comparative
analyses and the absence of non-Amgen trials of DA.
The results of the comparative analysis conﬁrm that
DA is more effective than placebo at increasing serum
Hb levels and at reducing the need for transfusion in
patients with CIA when treatment is initiated at Hb
r10 g/dL, as per current product labeling. (Clin Ther.
2016;38:122–135) & 2016 The Authors. Published by
Elsevier HS Journals, Inc.
Key words: chemotherapy-induced anemia, darbe-
poetin alfa, hemoglobin, licensed indication, meta-
analysis, transfusion.INTRODUCTION
Chemotherapy-induced anemia (CIA) is common in
patients with cancer who are undergoing myelosuppres-
sive chemotherapy.1 In such patients, anemia has aVolume 38 Number 1
R. Pirker et al.detrimental effect on quality of life and can also nega-
tively affect the patient’s prognosis, increasing mortality
rates by up to 65%.2 In particular, anemia can often
lead to the need for transfusions, which are associated
with a range of issues, including the availability of
suitable blood, the checks necessary to ensure the
recipient’s safety (eg, transfusion-transmitted diseases),
the inconvenience to both patients and health care prof-
essionals, and the associated costs.2 Treatments, such as
erythropoiesis-stimulating agents (ESAs) that can in-
crease hemoglobin (Hb) concentrations and thereby
reduce the need for red blood cell transfusion2 are there-
fore of great beneﬁt to patients and health care systems.
In 2008, the summary of product characteristics for
the ESA darbepoetin alfa (DA) was updated, decreasing
the Hb treatment initiation and discontinuation thresh-
olds to r10 and 412 g/dL, respectively.3 This was
done as a result of data indicating that ESA treatment
in patients with cancer was potentially associated with
an increased risk of thromboembolic events and
mortality, and similar changes were made by the
Food and Drug Administration in the United States.4
Because most clinical trials that investigated the
effectiveness of DA in CIA were started before this
update, limited data are available to describe the
effectiveness of DA in terms of Hb and transfusion
outcomes when initiated at Hb r10 g/dL. The land-
mark registration Phase III placebo-controlled trials of
DA, for example, included patients when their Hb was
o11 g/dL, and the dose of blinded study drug was
withheld if a patient’s Hb concentration increased to
415.0 g/dL (for men) or 414.0 g/dL (for women).5,6
After the patient’s Hb concentration decreased to 13.0
g/dL, administration of the study drug was reinstated
at 50% of the previous dose.
Several meta-analyses and systematic reviews have
assessed the safety proﬁle of ESAs in CIA, analyzed
results in individual tumor types, and combined data
for different ESAs.7–16 These reviews found that ESA
treatment can improve Hb concentrations and/or
reduce the need for transfusion in patients with
CIA.10,13–16 Some reviews also suggest that ESA
treatment can increase the rate of mortality when
used inappropriately in patients with CIA,7,8,12,15
although others have found no increase in that rate
of mortality.9,11,13,14,16 These reviews have not, how-
ever, evaluated the effectiveness of DA in terms of Hb
and transfusion outcomes in the subgroup of patients
with a baseline Hb r10 g/dL.January 2016We conducted a pooled analysis and meta-analysis
that were based on data from Amgen-sponsored DA
trials to assess the effectiveness of DA in CIA in
patients who initiated DA at Hb r10 g/dL.METHODS
Objectives
The objective of this analysis was to summarize
data on the effectiveness of DA when used according
to the revised prescribing information and recommen-
dations with an Hb treatment initiation threshold
r10 g/dL for CIA. Effectiveness was assessed in terms
of achievement of Hb targets (increase ofZ1 g/dL and
Z2 g/dL) and transfusion requirements.
Study Design
Data were sourced from a central database of
Amgen-sponsored trials of DA in CIA. For compara-
tive analyses, randomized controlled trials of DA in
CIA that had at least 1 arm of a prespeciﬁed DA
regimen versus control (placebo/best supportive care)
were eligible for selection. Only data for DA arm(s) of
permitted DA regimens and control data were ex-
tracted and were limited to patients who initiated DA
at r10 g/L. For supportive analyses (DA-only anal-
yses), randomized multiple-arm or prospective single-
arm trials of DA in CIA that had at least 1 arm of a
prespeciﬁed DA regimen were selected. Again, only
data for DA arm(s) of permitted DA regimens were
extracted and were limited to patients who initiated
DA at r10 g/dL. Prespeciﬁed permitted DA regimens
were 6.75 μg/kg (500 μg) every 3 weeks (Q3W), 2.25
μg/kg (150 μg) weekly (QW), 4.5 μg/kg (300 μg)
Q3W, any 2-weekly regimen, and the QW 4.5 μg/kg
(300 μg) front-loading dose regimen (ie, a high initial
dose with the intention of subsequently reducing the
dose and/or dose interval). Studies of 4-weekly DA,
and all dose-ﬁnding studies, were excluded. In the DA-
only analysis, data were analyzed separately for front-
loading and non–front-loading DA regimens, because
front-loading dosing is not licensed for DA. This was
not done for the comparative analysis because the
number of studies was too small.
Outcomes and Analyses
Outcomes included the percentage of patients with
an Hb increase Z1 g/dL or Z2 g/dL, time to ﬁrst Hb
increase Z1 g/dL or Z2 g/dL, the percentage of123
Table I. Randomized, controlled studies included in the comparative analysis.
Study Cancer Population
Treatment
Duration (wk)
Screening Hb
Concentration
for Study
Inclusion (g/dL)
Initial DA
Dose
Hb Indication for
Transfusion (g/dL)
Total Patients
Enrolled Who
Received Study
Drug (n)
Patients
with Hb
r10 g/dL at
Baseline (n)
Percentage
of Total
Patients (%)DA Placebo DA Placebo
Hedenus
et al5
Lymphoproliferative
malignancies
12 o11 2.25 μg/kg/wk o8* 174 170 107 105 62
Pirker et al21 Small-cell lung
cancer
18 r13 300 μg QW NS 299 289 12 18 5
Hernandez
et al22
Non-myeloid
malignancy
15 o11 300 μg Q3W r8† 193 193 85 83 44
Vansteenkiste
et al6
Lung cancer 12 o11 2.25 μg/kg/wk r8* 156 158 57 67 39
Total (4 studies) 822 810 261 273 33
DA ¼ darbepoetin alfa; Hb ¼ hemoglobin; NS ¼ not speciﬁed; QW ¼ every week; Q3W ¼ every 3 weeks.
*Recommended concentration; initiation of transfusion at the discretion of the investigators.
†Transfusions with Hb 48 g/dL were allowed if signs or symptoms of anemia were present.
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Table II. Studies with darbepoetin arms included in the darbepoetin alfa-only non–front-loading dose analyses.
Study Cancer Population
Treatment
Duration
(wk)
Screening Hb
Concentration
for Study
Inclusion
(g/dL) Initial DA Dose
Hb Indication
for Transfusion
(g/dL) Control
Total Patients
Enrolled Who
Received
Study Drug
(n)
DA Patients
with Hb
r10g/dL at
Baseline (n)
Percentage
of Total
Patients
(%)
Vansteenkiste
et al6
Lung 12 o11 2.25 μg/kg/wk r8* Placebo 156 57 37
Hedenus
et al19
Lymphoproliferative
malignancy
12 r11 2.25 μg/kg/wk r8* Placebo 174 107 61
Vadhan-Raj
et al23
Non-myeloid
malignancy
15 r11 3.0 μg/kg Q2W As medically
needed
None 1173 543 46
Glaspy et al24 Non-myeloid
malignancy
16 r11 6.75 μg/kg
Q3W
NS None 81 29 36
Gabrilove
et al25
Non-myeloid
malignancy
26 r11 200 μg Q2W As medically
needed
None 2401 994 41
Senecal
et al26
Breast 16 o11 200 μg Q2W o8* Epoetin
alfa
72 18 25
Schwartzberg
et al27
Non–small-cell lung
cancer
16 r11 200 μg Q2W NS Epoetin
alfa
51 13 25
Schwartzberg
et al27
Gynecologic
malignancy
16 r11 200 μg Q2W NS Epoetin
alfa
34 16 47
Glaspy et al28 Non-myeloid
malignancy
16 r11 200 μg Q2W r8† Epoetin
alfa
606 235 39
Boccia et al29 Various tumors 13 o11 300 μg Q3W NS None 1493 583 39
Canon et al30 Non-myeloid
malignancy
15 o11 500 μg Q3W r8‡ None 705 378 54
2.25 μg/kg QW
Hernandez
et al22
Non-myeloid
malignancy
15 o11 300 μg Q3W r8† Placebo 193 85 44
Bastit et al31 Non-myeloid
malignancy
16 o11 500 μg Q3W r8* None 396 183 46
Schwartzberg
et al32
Non-myeloid
malignancy
25 o11 150 μg QW NS None 752 340 45
300 μg Q2W
500 μg Q3W
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126patients who received a red blood cell transfusion
from the start of week 5 (day 29), and time to ﬁrst
transfusion from day 29. Analyses were limited to
data up to 12 weeks after the initiation of DA or
control. Outcomes were also analyzed in subgroups of
patients with Hb at treatment initiation o9 g/dL
versus 9 to r10 g/dL.
For the comparative analysis, and separately for the
DA-only analysis, study data were pooled to calculate
crude and Kaplan–Meier percentages and time to each
outcome of interest by treatment arm (DA or placebo
for the comparative analysis; DA for the DA-only
analysis). Kaplan–Meier plots were used to summarize
time to each outcome of interest graphically. Crude
percentages were calculated together with a Wilsons
95% CI.17 The CI for Kaplan–Meier percentages were
calculated by taking 1 minus the survivor function at the
last noncensored time point (Greenwoods formula18).
For the comparative analysis only, meta-analysis
techniques were used to calculate treatment effect for
DA. An inverse-variance method was used (for both a
random [DerSimonian–Laird] and ﬁxed-effect model)
on the basis of hazard ratios (HRs). I2 statistics for
heterogeneity were also calculated.
To conﬁrm that exclusion of dose-ﬁnding studies in
the original study design did not affect the overall
ﬁndings, sensitivity analyses for the comparative
analysis were conducted, including data from 2 DA
dose-ﬁnding studies.19,20RESULTS
Studies Included
The database review identiﬁed 4 studies that met the
inclusion and exclusion criteria for the comparative
analysis (DA, n = 261; placebo, n = 273)
(Table I).5,6,21,22 All 4 studies were Phase III random-
ized, double-blind, placebo-controlled trials. In addi-
tion, 2 placebo-controlled dose-ﬁnding studies were
identiﬁed that included patients who initiated treatment
at Hbr10 g/dL. These studies were excluded from the
main analysis but were included in a sensitivity anal-
ysis. The database review for the DA-only analysis
identiﬁed 15 relevant non–front-loading studies
(n = 3768; Table II)6,19,23–33 and 6 front-loading
studies (n = 901; see Supplemental Table I in the
online version at http://dx.doi.org/10.1016/j.clinthera.
2015.11.012). Here, we focus on the comparative
analysis and non–front-loading DA-only analysis.Volume 38 Number 1
Table III. Baseline characteristics of patients in the comparative analysis and the DA-only analysis (non–front-
loading).
Comparative Analysis DA-Only Analysis (non–front-loading)
DA (n ¼ 261) Placebo (n ¼ 273) DA (n ¼ 3768)
Male sex, n (%) 135 (52) 143 (52) 1489 (40)
Age, y, mean [SD] 64.5 [12] 63.0 [12] 62.2 [13]
Age o65 y, n (%) 115 (44) 139 (51) 2017 (54)
Tumor type, n (%)
Breast 25 (10) 11 (4) 729 (19)
Gastrointestinal 8 (3) 13 (5) 740 (20)
Genitourinary 7 (3) 4 (2) 200 (5)
Gynecologic 9 (3) 6 (2) 340 (9)
Hematologic 119 (46) 128 (47) 636 (17)
Lung 80 (31) 99 (36) 804 (21)
Other 13 (5) 12 (4) 319 (8)
Disease stage, n (%)
Stage II or lower/limited 33 (13) 43 (16) 608 (16)
Stage III or higher/extensive 218 (84) 213 (78) 2854 (76)
Missing/other 10 (4) 17 (6) 306 (8)
ECOG performance status, n (%)
0 53 (20) 44 (16) 1227 (33)
1 121 (46) 131 (48) 2026 (54)
2 44 (17) 54 (20) 370 (10)
3 4 (2) 4 (2) 7 (o1)
Missing 39 (15) 40 (15) 138 (4)
Hemoglobin, g/dL, mean [SD] 9.1 [0.7] 9.1 [0.8] 9.3 [0.6]
DA ¼ darbepoetin alfa, ECOG ¼ Eastern Cooperative Oncology Group.
R. Pirker et al.Baseline characteristics of the included patients are
shown in Table III. Hematologic and lung cancers were
the most common malignancies in the comparative
analysis, and lung, gastrointestinal, breast, and hematolo-
gic cancers were most common in the DA-only analysis.
Baseline age, disease stage, performance status, and Hb
concentrations were similar for the DA and placebo
groups of the comparative analysis and the population
included in the DA-only analysis; average age across these
groups ranged from 62.2 to 64.5 years, 475% of pati-
ents had disease stage III or higher (or extensive disease),
and most patients had an Eastern Cooperative Oncology
Group performance status of 0 or 1. Baseline Hb was
9.1 g/dL in the DA and placebo groups of the compara-
tive analysis and 9.3 g/dL in the DA-only analysis.January 2016Comparative Analysis
Mean Hb concentrations over time are shown in
Figure 1. On the basis of crude and Kaplan–Meier
percentages, more patients who received DA achieved
an increase in Hb of Z1 g/dL or Z2 g/dL versus
placebo (Table IV). Fixed-effect HRs for patients
with an Hb increase of Z1 g/dL and Z2 g/dL
for DA versus placebo were 2.07 (95% CI, 1.62–
2.63) and 2.91 (95% CI, 2.09–4.06), respectively
(Figure 2). Median time to a Z1 g/dL increase
was 43 days (95% CI, 37–50 days) for DA and
was not evaluable (NE) for placebo (Figure 3A).
Median time to a Z2 g/dL increase was 78 days
(95% CI, 71–NE days) for DA and was NE for
placebo (Figure 3B).127
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Figure 1. Mean hemoglobin concentrations during the first 12 weeks of treatment in the (A) comparative and
(B) darbepoetin alfa-only non–front-loading analyses. Error bars represent 95% CIs.
Clinical TherapeuticsThe crude and Kaplan–Meier percentages of DA-
treated patients who achieved Hb increases Z1 g/dL
andZ2 g/dL were similar in the subgroups of patients
with baseline Hb o9 g/dL or Hb 9 to r10 g/dL
(Table IV). Fixed-effect HRs for an Hb increase of
Z1 g/dL and Z2 g/dL for DA versus placebo were
1.61 (95% CI, 1.05–2.46) and 1.72 (95% CI, 1.03–
2.85), respectively, for the Hbo9 g/dL subgroup, and
2.31 (95% CI, 1.72–3.11) and 3.70 (95% CI, 2.36–
5.81) for the Hb 9 to r10 g/dL subgroup. In patients
with baseline Hbo9 g/dL, median time to a Z1 g/dL
increase was 49 days (95% CI, 43–52 days) for DA
and 77 days (95% CI, 57–NE days) for placebo. In128patients with baseline Hb 9 tor10 g/dL, median time
to a Z1 g/dL increase was 43 days (95% CI, 29–50
days) for DA and NE for placebo.
On the basis of crude and Kaplan–Meier percen-
tages, transfusions were more commonly required
between the start of week 5 and end of week 12 in
patients who received placebo than in patients who
received DA (Table IV). Fixed-effect HR for DA
versus placebo was 0.58 (95% CI, 0.44–0.77)
(Figure 2C). More patients with a baseline Hb o9
g/dL needed transfusions than patients with a baseline
Hb 9 to r10 g/dL in both the DA and placebo arms
(Table IV).Volume 38 Number 1
Table IV. Summary of patients with an increase in Hb Z1 g/dL or Z2 g/dL during the first 12 weeks of
treatment or who required a transfusion (red blood cell or whole blood) from start of week 5 to
end of treatment.
Crude analysis Kaplan–Meier Analysis
Comparative Analysis
DA-Only Analysis
(non–front-loading)
Comparative Analysis
DA-Only Analysis
(non-front-loading)DA Placebo DA Placebo
All patients, n 261 273 3768 261 273 3768
Hb Z1 g/dL 66 (60–71) 40 (35–46) 67 (65–68) 76 (69–83) 48 (40–57) 82 (80–85)
Hb Z2 g/dL 45 (39–51) 19 (15–24) 43 (42–45) 58 (49–68) 27 (18–37) 60 (57–63)
Transfusion 33 (27–39) 49 (43–55) 23 (22–25) 34 (28–40) 51 (45–57) 25 (23–26)
Baseline Hb o9
g/dL, n
96 80 968 96 80 968
Hb Z1 g/dL 63 (53–72) 45 (35–56) 66 (63–69) 71 (61–81) 53 (41–66) 81 (77–85)
Hb Z2 g/dL 47 (37–57) 30 (21–41) 46 (43–49) 59 (46–73) 37 (25–49) 66 (60–72)
Transfusion 43 (33–53) 58 (47–69) 35 (32–38) 44 (34–55) 61 (50–73) 37 (34–41)
Baseline Hb
9–r10 g/dL, n
165 193 2800 165 193 2800
Hb Z1 g/dL 68 (60–75) 38 (32–45) 67 (66–69) 79 (69–88) 46 (36–57) 83 (80–85)
Hb Z2 g/dL 44 (36–51) 15 (10–20) 42 (40–44) 57 (45–69) 24 (12–35) 58 (55–61)
Transfusion 26 (20–34) 45 (38–53) 19 (18–21) 27 (20–35) 47 (40–54) 21 (19–22)
Values are percentage (95% CI), unless otherwise indicated.
DA ¼ darbepoetin alfa; Hb ¼ hemoglobin.
R. Pirker et al.Sensitivity Analyses
The sensitivity analysis included 2 additional
randomized, placebo-controlled, dose-ﬁnding stud-
ies,19,20 providing an overall total of 598 patients
(DA, n = 313; placebo, n = 285). Inclusion of these 2
studies did not change the interpretation of the
efﬁcacy ﬁndings from the main comparative analysis.
DA-Only Analysis (non–front-loading data)
Mean Hb concentrations over time in the non–front-
loading dose analysis are shown in Figure 1B. The crude
and Kaplan–Meier percentages of patients who achieved
aZ1 g/dL orZ2 g/dL increase in Hb were similar to the
percentages seen for DA in the comparative analysis
(Table IV). Overall, the median time to an Hb increase
Z1 g/dL was 43 days (95% CI, 43–43 days) (Figure 4A),
and to an Hb increase ofZ2 g/dL was 78 days (95% CI,
74–78 days) (Figure 4B). Results in patients with baseline
Hbo9 g/dL or 9 toZ10 g/dL were similar to results forJanuary 2016ther10 g/dL population in terms of crude and Kaplan–
Meier percentages of patients who achieved a Z1 g/dL
or Z2 g/dL increase in Hb (Table IV) and time to Hb
increase 1 g/dL or 2 g/dL (data not shown).
The percentages of patients who required a trans-
fusion on the basis of crude and Kaplan–Meier
percentages were similar to those in the comparative
analysis (Table IV). Again, more patients with a
baseline Hb o9 g/dL needed transfusions than
patients with a baseline Hb 9 to r10 g/dL.
Results in the front-loading studies were similar to
those in the non–front-loading studies (see online-only
supplement).
DISCUSSION
This is the ﬁrst patient-level meta-analysis, to our
knowledge, to evaluate the efﬁcacy, in terms of Hb
response, of DA treatment when initiated according
to the current product labeling in patients with CIA.129
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Clinical TherapeuticsThe results of the comparative analysis conﬁrm that
DA is more effective than placebo at increasing serum
Hb concentrations and at reducing the need for trans-
fusion in patients with CIA when treatment is initiated130at Hb r10 g/dL. Addition of 2 dose-ﬁnding studies
did not change the ﬁndings of the main comparative
analysis, and the results were consistent with the DA-
only analyses, which included larger patient cohorts.Volume 38 Number 1
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Figure 3. Kaplan–Meier curves for time to (A) increase in hemoglobin ofZ1 g/dL during the first 12 weeks of
treatment and (B) increase in hemoglobin of Z2 g/dL during the first 12 weeks of treatment
(comparative analysis).
R. Pirker et al.The results of this analysis are consistent with
previously published observational studies, post hoc
analyses, chart reviews, and single-center studies of DA,
which reported data on the efﬁcacy of DA when
initiated at Hbr10 g/dL.34–41 For example, data from
the CHOICE observational study in 1887 patients with
solid tumors and CIA who received DA for 9 weeks
found that 29% of patients who initiated treatment at
Hb o9 g/dL and 20% of patients who initiated
treatment at Hb 9 to o10 g/dL required a transfusion
between the start of week 5 and end of treatment.39 In
a post hoc analysis of a Phase III study in patients with
non-myeloid malignancies and CIA, Kaplan–Meier
transfusion incidences with Q3W and QW DA wereJanuary 201636% and 41%, respectively, in patients who initiated
treatment at Hb o10 g/dL.40 Similarly, post hoc
analysis of an earlier study in patients with lung
cancer and CIA found that transfusion incidence with
weekly DA was 31%.40 The results of the present study
are also consistent with studies of DA in patients with a
broader range of baseline Hb concentrations, including
those 410 g/dL.6,20,22,28,30
Notably, the present analysis indicates similar
efﬁcacy outcomes regardless of whether DA was
initiated at Hb concentrations o9 g/dL or 9 to
r10 g/dL, although the need for transfusions was
numerically higher in patients in the lower Hb
category. This is consistent with an earlier exploratory131
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Figure 4. Kaplan–Meier curves for time to (A) increase in hemoglobin ofZ1 g/dL during the first 12 weeks of
treatment and (B) increase in hemoglobin of Z2 g/dL during the first 12 weeks of treatment
(darbepoetin alfa-only analysis, non–front-loading).
Clinical Therapeuticsanalysis of data from a 15-week clinical trial by
Canon et al35 in which patients received DA 500 μg
Q3W or 2.25 μg/kg QW. Results of that analysis
suggested that baseline Hb o9 g/dL (n ¼ 126) was
associated with worse outcomes than 9 to r10 g/dL
(n ¼ 225) in terms of aZ1 g/dL increase in Hb within
14 days, and for achievement of Hb Z10 g/dL and
need for transfusion. The researchers therefore
recommended that treatment be initiated as soon as
possible after Hb falls to 10 g/dL.35
The strength of the present study is in the pooling
of effectiveness data from multiple studies, partic-
ularly for the DA-only analyses; we recognize that a
limited number of studies and patients were eligible132for inclusion in the comparative analyses. Notably,
the included studies were designed when DA was
generally initiated at a higher Hb threshold, so only
those data from the subset of patients who initiated
Hb at r10 g/dL were extracted. In addition, this
analysis of short-term (r26-week) studies focused
on assessing the efﬁcacy of DA speciﬁcally in
patients whose treatment was initiated at the lower
Hb threshold introduced by regulatory bodies in
2008. Analysis of longer-term end points in these
patients, including key adverse events and survival,
would be of great interest. Finally, it should be
noted that non-Amgen trials of DA were not
included.Volume 38 Number 1
R. Pirker et al.CONCLUSIONS
The results of this pooled analysis suggest that DA is
effective at rapidly increasing Hb concentrations and
reducing the need for transfusions in patients with
CIA when initiated after Hb falls to r10 g/dL, as per
current product labeling.
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Clinical TherapeuticsSUPPLEMENTARY MATERIALS
Darbepoetin-only Front-loading Analyses
The database review for the darbepoetin alfa (DA)-
only analysis identiﬁed 6 front-loading studies
(n¼901; Supplementary Table I). Baseline charac-
teristics of the included patients (Supplementary
Table II) were similar to those in the comparative
and non-front-loading DA-only analyses.
Mean hemoglobin (Hb) levels over time are shown
in Supplementary Figure 1. In the analysis of front-
loading DA doses, the crude and Kaplan–Meier
percentages of patients achieving a Z1 g/dL or Z2
g/dL increase in Hb were generally similar, or slightly
higher than the percentages seen for DA in the
comparative and non-front-loading DA-only analyses
(Supplementary Table III). Overall, the median12.0
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Figure S1. Mean hemoglobin levels during the first 12
loading analyses. Error bars represent 95% c
135.e1(95% conﬁdence interval [CI]) time to an Hb increase
Z1 g/dL was 35 (29–36) days (Supplementary
Figure 2a); the median (95% CI) time to an Hb
increase Z2 g/dL was 64 (57–71) days (Supplementary
Figure 2b). Results in patients with baseline Hbo9 g/dL
or 9–Z10 g/dL were similar to those for the r10 g/dL
population in terms of crude and Kaplan–Meier
percentages of patients achieving a Z1 g/dL or
Z2 g/dL increase in Hb (Supplementary Table III), and
time to Hb increase 1 g/dL or 2 g/dL (data not shown).
The percentages of patients requiring a transfusion
based on crude and Kaplan–Meier percentages were
similar to those in the comparative and non-front-
loading DA only analyses (Supplementary Table III).
Again, more patients with a baseline Hb o9 g/dL
needed transfusions than those with a baseline Hb
9–r10 g/dL.6 7 8 9 10 11 12
563
tudy week
558 539 518 528 503 470
weeks of treatment in the darbepoetin-only front-
onfidence intervals.
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Figure S2. Kaplan–Meier curve for time to a) increase in hemoglobin ofZ1 g/dL during the first 12 weeks of
treatment, and b) increase in hemoglobin of Z2 g/dL during the first 12 weeks of treatment in
patients receiving darbepoetin alfa (darbepoetin-only non-front-loading analysis).
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Supplementary Table I. Studies with darbepoetin arms included in the darbepoetin-alfa-only front-loading dose analyses.
Study Cancer population
Treatment
duration
(weeks)
Screening
Hb level for
study
inclusion Initial DA dose Control
Hb indication for
transfusion
Total patients
enrolled who
received study
drug (n)
DA patients with
Hb r10g/dL at
baseline (n)
% of total
patients
Glaspy et al.
2003
Solid tumors 12 r11 g/dL 4.5 μg/kg/week Epoetin alfa r8 g/dL* 92 53 58
ClinicalTrials.
gov:
NCT00038
064
Non-myeloid
malignancy
16 r11 g/dL 4.5 μg/kg/week Epoetin alfa NS 353 183 52
Hesketh et al.
2004
Non-myeloid
malignancy
16 o11 g/dL 4.5 μg/kg/week None r8 g/dL† 242 75 31
325 μg QW
Pirker et al. 2008 Small-cell lung cancer 18 r13 g/dL 300 μg QW Placebo NS 299 12 4
Kotasek et al.
2007
Non-myeloid
malignancy
16 r11 g/dL 4.5 μg/kg/week None r8 g/dL† 723 439 61
2.25 μg/kg/week
ClinicalTrials.
gov:
NCT0011
1137
Non-myeloid
malignancy
12 r11 g/dL 4.5 μg/kg/week Epoetin alfa NS 353 139 39
Total (6 studies) 2062 901 44
DA ¼ darbepoetin alfa; Hb ¼ hemoglobin; QW ¼ every week; Q2W ¼ every 2 weeks; Q3W ¼ every 3 weeks.
*Transfusion with Hb 48 g/dL allowed if medically indicated.
†Recommended level; initiation of transfusion at the discretion of the investigators.
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Supplementary Table II. Baseline characteristics of patients included in the darbepoetin-alfa-only front-
loading dose analyses.
Darbepoetin alfa (n ¼ 901)
Male sex, n (%) 374 (42)
Age (years), mean [SD] 62.0 [13]
Age o65 years, n (%) 475 (53)
Tumor type, n (%)
Breast 139 (15)
Gastrointestinal 173 (19)
Genitourinary 43 (5)
Gynecological 80 (9)
Hematological 222 (25)
Lung 170 (19)
Other 74 (8)
Disease stage, n (%)
Stage II or lower/limited 91 (10)
Stage III or higher/extensive 729 (81)
Missing/other 81 (9)
ECOG performance status, n (%)
0 225 (25)
1 400 (44)
2 100 (11)
3 3 (o1)
Missing 173 (19)
Hemoglobin (g/dL), mean [SD] 9.2 [0.7]
ECOG ¼ Eastern Cooperative Oncology Group; SD ¼ standard deviation.
R. Pirker et al.
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Supplementary Table III. Summary of percentage (95% confidence interval) of patients with an increase in
hemoglobin (Hb) Z1 g/dL or Z2 g/dL during the first 12 weeks of treatment or
requiring a transfusion (red blood cell or whole blood) from start of week 5 to end
of treatment in the darbepoetin-alfa-only front-loading dose analyses.
Crude analysis Kaplan–Meier analysis
All patients (n¼901) (n¼901)
Hb Z1 g/dL 70 (67–73) 81 (77–84)
Hb Z2 g/dL 51 (48–55) 65 (60–70)
Transfusion 26 (24–30) 28 (25–31)
Baseline Hb o9 g/dL (n¼290) (n¼290)
Hb Z1 g/dL 68 (62–73) 77 (71–83)
Hb Z2 g/dL 56 (50–62) 69 (61–77)
Transfusion 36 (30–42) 38 (32–44)
Baseline Hb 9–r10 g/dL (n¼611) (n¼611)
Hb Z1 g/dL 72 (68–75) 83 (78–87)
Hb Z2 g/dL 49 (45–54) 63 (56–70)
Transfusion 22 (19–26) 24 (20–27)
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